Chemorepulsion of cells
AssigneeCeltaxsys, Inc.
InventorsHyun Kang, Scott Sacane, Jonathan L. Moon, Erica B. Goodhew, Lopa Bhatt, Stacey L. Rose, Milton H. Werner
Life of this patent
Estimating the term…
Abstract
The present invention provides compositions and methods of controlling the direction and/or movement of migratory cells. Specifically, the invention is directed to the identification of novel chemorepellents and unimodal fugetaxins, their agonists and antagonists which alter or affect the movement of cells involved in immune, inflammatory or cancerous phenotypes.
Claims22
A method of inducing negative chemotaxis in human migratory cells comprising contacting said human migratory cells with a validated chemorepellent.
(canceled)
(canceled)
(canceled)
18-22. (canceled)
A method of inducing negative chemotaxis in human eosinophils comprising contacting said human eosinophils with a chemorepellent, said chemorepellent selected from the group consisting of galectin-1, galectin-2, heat shock protein 27, heat shock protein 40, heat shock protein 47, heat shock protein 70, heat shock protein 90, Pam3CSK4, HKLM (heat killed L. monocytogenes), Poly(I:C), FLS-1, imiquimod, paclitaxel, Lipid A Diphos, P. gingavalis LPS, Lipomannan M. smegmatis, LTA Staph, Standard LTA from S. aureus, N-acetylmuramyl (MDP), cathespin G, resveratrol and quercetin dehydrate.
A method of ameliorating an inflammatory response in a subject comprising:
- a. identifying a subject having undergone an inflammatory insult or stimulus, and
- b. contacting said subject with a validated chemorepellent at a site of inflammatory response to said inflammatory insult or stimulus in an amount effective to induce negative chemotaxis of at least a portion of a population of immune cells which comprise said inflammatory response.
Dependencies are inferred from the claim text.